Interpares Biomedicine, Inc. is an early-stage medical therapeutics company focused on providing personalized medicine solutions to inform cancer immunotherapy decisions. Interpares Biomedicine provides guidance on immunooncology selection for patients with metastatic solid tumors, without the need for tissue biopsy. Interpares will provide a CLIA/CAP reference laboratory, with initial tests being blood-based proprietary predictors of benefit from CTLA-4 and PD-1 inhibitors. The pipeline includes markers of severe/life threatening immunotherapy toxicity, predictors of altered efficacy, and guidance for single agent versus combination immunotherapy. Interpares is well positioned to provide essential information to drug developers, clinical oncologists, and healthcare payers as they optimize the application of the many new immunotherapy options for cancer treatment.